Brano Therapeutics
Singapore’s Brano Therapeutics raises $6.8M seed funding to advance heart failure treatments
Brano Therapeutics, a spin-off from Singapore's Duke-NUS Medical School, has secured $6.8 million in seed funding to support the development of new treatments for heart failure, including heart failure with preserved ejection fraction (HFpEF), a condition with limited therapeutic options.
